News & Updates

Pregnancies in women who have survived cervical cancer or leukaemia should be considered high-risk due to the potential for multiple severe obstetric complications, as reported in a study.

In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.